Julie Rachline

Julie Rachline joined Advicenne in November 2015 to support corporate development and investor relations.

As a private equity investor, Julie invested in diverse companies such as BrainEver, HalioDx, Nanobiotix (Ticker: NANO) and Eurogentec (sold to Kaneka), serving on the boards of these companies as well as those of Voluntis and Stimulus. As a former Principal at L3S partnership, where she was involved in or led recruitments for pharma, medtech, ANSM and the French Biomedicine Agency (Agence de la Biomédecine), Julie also brings to her work at Advicenne a strong background in executive search.

Julie holds a PhD in Neuropharmacology from Ecole Normale Supérieure and an MS from ESCP Europe.